.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX03_Catumaxomab.Catumaxomab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX03_Catumaxomab.Catumaxomab| name: | Catumaxomab |
| ATC code: | L01FX03 | route: | intraperitoneal |
| n-compartments | 2 |
Catumaxomab is a trifunctional monoclonal antibody used in the treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible. It acts by binding to EpCAM on tumor cells, CD3 on T-cells, and Fcγ receptors on accessory cells to induce tumor cell lysis. It was granted orphan drug status and previously approved in the EU but marketing authorization was withdrawn in 2017; it is not currently approved for routine clinical use.
Pharmacokinetic estimation in adult cancer patients after intraperitoneal (i.p.) administration, as data from original studies is scarce and no human PK model with explicit compartmental parameters is published.